Ovagen
RecoveryPreclinicalAlso known as: GI peptide
Ovagen is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as an "ovarian bioregulator" intended to support female reproductive tissue, follicular reserve markers, and age-related ovarian decline, as well as broader hepatobiliary function in some historical formulations.
Overview
At A Glance
Mechanism of Action…
Mechanism of Action
Mechanism of Action
Ovagen's proposed mechanism is the Khavinson short-peptide framework applied to ovarian tissue: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing ovarian-favourable transcriptional shifts.
Step 1 — Tissue distribution. At ~446 daltons (H-Lys-Glu-Asp-Gly-OH), Ovagen is small and sufficiently polar to cross phospholipid bilayers passively. Khavinson tritiated-peptide biodistribution work describes uptake across multiple tissues including ovary, liver, kidney, and brain (Khavinson et al., 2014). The ovary has a complex vascular supply and follicles exist at different stages of maturation (primordial, primary, secondary, antral), each with different cellular composition and barrier properties. Whether Ovagen reaches granulosa, theca, or oocyte nuclei at functionally meaningful concentrations has not been established by modern pharmacokinetic methodology.
Step 2 — Ovarian cell targeting. The Khavinson-framework claim is that KEDG reaches ovarian follicular cells and modulates chromatin in an ovarian-specific manner. No structural biology, no follicle-specific transcriptomic data, and no modern target validation has been published. The tissue-specific targeting claim rests on extrapolation from the bioregulator framework rather than direct evidence.
Step 3 — Chromatin modulation of ovarian programmes. Russian in vitro work describes preservation of follicular cell viability under stress conditions, reduced apoptosis markers in granulosa cells exposed to Ovagen, and modulation of steroidogenic enzyme expression in cultured ovarian cells (Chalisova et al., 2015). The proposed mechanism is preferential activation of follicular survival and steroidogenic transcription programmes. Modern reproductive biology methodology — single-cell transcriptomics of ovarian follicles, ChIP-seq in granulosa cells, iPSC-derived oocyte models — has not been applied to Ovagen.
Alternative conservative framing
A parsimonious interpretation treats Ovagen as an amino-acid source delivering lysine, glutamate, aspartate, and glycine in rapidly hydrolysed tetrapeptide form. Biological effects could reflect: (a) substrate delivery for rapidly-dividing granulosa cell protein synthesis, (b) glycine-mediated effects on glutathione synthesis and antioxidant defence in follicles, (c) non-specific nutritional support under oxidative stress conditions common to aging ovary, or (d) simple amino-acid provision equivalent to dietary protein sources. Under this framing, any amino-acid mixture would produce similar effects.
Comparison to evidence-graded reproductive-aging interventions
Evidence-based management of reproductive aging has defined mechanisms:
- Estradiol — steroid hormone binding estrogen receptors ERα/ERβ, producing well-characterised transcriptional effects. Decades of RCT data for menopausal symptom management (Women's Health Initiative and subsequent analyses).
- Progestogens — progesterone receptor agonists, endometrial protection when estrogen is administered in intact uterus, mechanism mapped.
- GnRH agonists and antagonists — pituitary-gonadotropin axis modulation, clinically validated in IVF, endometriosis, fibroids.
- Clomiphene and letrozole — ovulation induction via estrogen receptor modulation or aromatase inhibition, RCT-validated.
- Gonadotropins (FSH, LH, hCG) — direct ovarian stimulation, IVF-validated.
- Myo-inositol — cellular signalling modulator with RCT evidence in PCOS-related ovarian dysfunction.
- CoQ10 — mitochondrial electron transport, modest RCT evidence for ovarian function in aging women.
Ovagen sits at a fundamentally different level of mechanism specification — framework-level hypothesis rather than measured pharmacology.
Comparison to other peptides for reproductive tissue
Gonadotropin-releasing hormone (GnRH) and its analogues (leuprolide, triptorelin, cetrorelix) are well-characterised peptides with defined ovarian effects via pituitary modulation. Human chorionic gonadotropin (hCG) is a glycoprotein with LH-like activity. Kisspeptin and analogues are emerging reproductive peptides with well-characterised receptor pharmacology. Among reproductive peptides, Ovagen has the least molecular-biology characterisation.
Receptor pharmacology
No GPCR, nuclear receptor, or defined enzyme target identified for Ovagen. It does not bind estrogen receptors, progesterone receptors, FSH receptor, LH receptor, GnRH receptor, or any characterised reproductive pharmacology target. The absence of defined target is characteristic of the Khavinson bioregulator class.
Relation to Testagen
Testagen is positioned as the male-reproductive bioregulator counterpart to Ovagen in the Khavinson framework. Same mechanistic framework, different tissue target. Neither has modern molecular validation.
Overview
Ovagen is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as an "ovarian bioregulator" intended to support female reproductive tissue, follicular reserve markers, and age-related ovarian decline, as well as broader hepatobiliary function in some historical formulations. It is usually described in Khavinson-family publications as the tetrapeptide Lys-Glu-Asp-Gly (KEDG), sometimes rendered H-Lys-Glu-Asp-Gly-OH or K-E-D-G. Ovagen sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, Cardiogen, Cartalax, and Chonluten within the Khavinson short-peptide bioregulator family, and is positioned as the female-reproductive counterpart to Testagen (male reproductive bioregulator).
Outside Russia, Ovagen is not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories, and does not appear in ASRM, ESHRE, or NICE guidelines for ovarian dysfunction, premature ovarian insufficiency, or menopause management. Published Russian work — authored primarily by Khavinson and collaborators — comprises in vitro ovarian follicle culture studies, rodent aging and ovariectomy experiments, and small uncontrolled observational series in women with age-related ovarian decline and perimenopausal transition (Khavinson et al., 2011; Anisimov et al., 2010; Kuznik et al., 2011).
The central claim for Ovagen is the standard Khavinson short-peptide bioregulator model applied to ovarian tissue: passive membrane permeation into granulosa and theca cells, nuclear import, and sequence-selective chromatin modulation producing preferential upregulation of follicular-survival, steroidogenic, and anti-apoptotic programmes. The tissue-specific targeting claim — that KEDG selectively supports ovarian rather than testicular, hepatic, or other tissue — is asserted but not supported by structural biology, modern biodistribution, or transcriptomic characterisation of ovarian tissue after KEDG exposure. The hypothesis is internally consistent within the Khavinson programme; it is substantially less validated than evidence-graded management of reproductive aging, perimenopause, and premature ovarian insufficiency.
BodyHackGuide covers Ovagen because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules) and appears occasionally in longevity and female-health discussions as a reproductive-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded management of reproductive aging toward interventions with substantial replication: complete hormonal assessment (FSH, LH, estradiol, AMH, thyroid, prolactin), lifestyle optimisation (weight management, smoking cessation, stress management), evidence-based hormone therapy when indicated and not contraindicated (estradiol + progestogen for perimenopausal symptoms, with individualised risk-benefit discussion), specific fertility treatment (ovulation induction, IVF) for age-related fertility decline, and proven supplements for reproductive aging (vitamin D, omega-3, CoQ10 with modest evidence for ovarian function, myo-inositol for PCOS). Ovagen is a plausible hypothesis. It is not, in 2026, an evidence-graded reproductive therapy.
Chemical Information
IUPAC Name
L-Lysyl-L-glutamyl-L-aspartyl-L-glutamine
CAS Number
Not yet available
Molecular Formula
Lys-Glu-Asp-Gln
Molecular Mass
489.49 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Contraindications
Absolute contraindications
- Pregnancy
- Breastfeeding
- Active conception attempts — avoid pending more safety data
- Paediatric and adolescent use
- Hormone-sensitive cancer (breast, endometrial, ovarian, cervical — active or recent history)
- Unexplained abnormal uterine bleeding — requires evaluation before any hormonal-framework intervention
- Active pelvic mass or gynaecological pathology under investigation
- Known hypersensitivity to Ovagen or any Khavinson bioregulator
Relative contraindications (supervised use only)
- Active IVF or fertility treatment — reproductive endocrinologist approval required
- Recent pelvic surgery — coordinate with surgeon
- History of VTE or thrombophilia — unquantified thrombotic risk
- History of hormone-sensitive benign conditions (large fibroids, endometriosis, atypical endometrial hyperplasia) — gynaecology coordination
- Severe liver disease
- Severe renal impairment (eGFR <30)
Use with caution
- Current HRT or hormonal contraception — no interaction data but compatibility appears acceptable
- PCOS management — do not substitute for evidence-based PCOS treatment
- Thyroid disease — treat thyroid, do not substitute Ovagen for thyroid therapy
Quality-of-supply contraindication
Do not use from vendors without third-party HPLC peptide content confirmation and endotoxin testing.
Symptoms requiring evaluation, not bioregulators
Abnormal uterine bleeding, new pelvic pain, new pelvic mass, unexplained weight loss, severe menopausal symptoms not responsive to standard care — require gynaecological/reproductive endocrinology evaluation, not Ovagen self-treatment.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Ovagen.
Related Compounds
View AllARA-290
RecoveryPreclinicalARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.
BPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
View Full Dosage Guide →
Protocols, calculator & safety for Ovagen
Research Score
19 PubMed studies
Quality Indicators
Data Completeness
88%Research Credibility
Quick Facts
Molecular Weight
489.49 g/mol
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Ovagen and what is it claimed to do?
Ovagen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly, KEDG) from Vladimir Khavinson's St. Petersburg Institute, positioned as a female reproductive/ovarian bioregulator for age-related ovarian decline, perimenopausal symptom management, and broader reproductive-tissue support. Claims include supporting follicular reserve, granulosa cell function, and steroidogenic programmes. Russian literature reports in vitro ovarian follicle culture effects and uncontrolled observational series in perimenopausal women (Chalisova et al., 2015; Khavinson et al., 2011). Not FDA/EMA-approved, not in any reproductive guideline (ASRM, ESHRE, NICE). Treat as experimental.
Does Ovagen actually help with perimenopause or fertility?
Honest answer: the evidence is thin. Russian uncontrolled observational series report subjective improvement in menopausal symptoms and modest biomarker changes. No placebo-controlled RCTs, no fertility outcome data (pregnancy rate, live-birth rate), no ovarian reserve imaging endpoints in formal trials. For perimenopause, evidence-graded first-line is individualised hormone therapy (estradiol + progestogen for intact uterus). For fertility, evidence-graded is reproductive endocrinology consultation with appropriate ovulation induction, IVF, or other interventions. Ovagen is not a substitute — it is a speculative adjunct.
What is the correct Ovagen dose?
Khavinson convention: 20 mg oral/sublingual capsule once daily for 10 consecutive days, with 60–90 day washouts. 20 mg capsule contains undisclosed actual KEDG content (historically 2–4 mg, balance excipients). For subcutaneous synthetic peptide, 2–5 mg daily for 10 days. No specific menstrual-cycle phase timing is recommended. No dose-ranging trial establishes 20 mg as optimal. Do not use during pregnancy, breastfeeding, or active conception attempts.
Is Ovagen safe?
Short-term safety signal from Russian literature is mild — occasional nausea, headache, transient cycle variation, rare rash. However, long-term pharmacovigilance is absent. Absolute contraindications include pregnancy, breastfeeding, active conception attempts (pending data), hormone-sensitive cancer (breast, endometrial, ovarian, cervical), unexplained abnormal uterine bleeding, and paediatric/adolescent use. Theoretical concerns about hormone-sensitive tumour risk and endometrial effects exist. Use only with third-party HPLC-verified product and gynaecological oversight.
Can I use Ovagen with HRT or hormonal contraception?
No documented interactions exist. Theoretically, Ovagen layered on top of estradiol-based HRT does not obviously conflict. Ovagen does not provide contraception. If on HRT for perimenopausal symptoms, continue it and add Ovagen as an experimental adjunct. If on combined hormonal contraception, continue it — Ovagen does not reliably affect ovulation or fertility. Notify your gynaecologist or reproductive endocrinologist of any bioregulator cycles.
Can I use Ovagen during IVF or fertility treatment?
Avoid without reproductive endocrinologist approval. Fertility treatments involve carefully controlled ovarian stimulation protocols with quantitative hormone monitoring. An unvalidated bioregulator introducing unknown effects into this environment is inappropriate. Do not run Ovagen during IVF cycles, ovulation induction, or IUI cycles. Coordinate with your reproductive endocrinologist before considering any experimental compounds in a fertility treatment context.
How does Ovagen compare to other Khavinson peptides?
Ovagen is the female reproductive member of the Khavinson tetrapeptide family, paired with Testagen (male reproductive). Both share the standard Khavinson chromatin-modulation framework. Ovagen sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, Cardiogen, Cartalax, and Chonluten. Evidence base is smaller than Epitalon (most-studied) or Thymogen (most regulatory recognition).
How does Ovagen compare to DHEA, CoQ10, and other fertility supplements?
CoQ10 200–600 mg daily has modest RCT evidence for mitochondrial support in aging oocytes. DHEA 25–50 mg daily has controversial but some RCT evidence for diminished ovarian reserve in assisted reproduction. Myo-inositol 2–4 g BID has RCT evidence in PCOS-related ovarian dysfunction. All three sit above Ovagen in evidence weight for specific reproductive applications. For a woman interested in reproductive-aging support, prioritise CoQ10, myo-inositol (if PCOS), and potentially DHEA (with reproductive endocrinologist guidance) before considering Ovagen.
Where do I source quality Ovagen?
Supply split between post-Soviet supplement vendors (20 mg oral capsules) and international research-peptide suppliers (lyophilised synthetic KEDG, requires reconstitution). Require third-party HPLC peptide content confirmation and endotoxin testing. Avoid vendors without certificate of analysis. Given reproductive-system application, quality verification is particularly important — contaminated or mislabeled peptide is especially problematic in this context.
If I have perimenopausal symptoms or fertility concerns and see a BodyHackGuide ad, what should I actually do?
Evidence-graded priority: (1) comprehensive endocrine assessment with your gynaecologist or reproductive endocrinologist — FSH, LH, estradiol, AMH, TSH, prolactin, reproductive history; (2) lifestyle optimisation — weight, smoking cessation, stress, sleep, exercise; (3) for severe perimenopausal symptoms, individualised hormone therapy discussion with gynaecology (estradiol + progestogen, transdermal preferred); (4) for fertility concerns, reproductive endocrinologist consultation with appropriate interventions (ovulation induction, IVF as indicated); (5) CoQ10 200–600 mg daily, myo-inositol 2–4 g BID (PCOS), vitamin D 1000–4000 IU daily, omega-3 2–4 g daily; (6) DHEA 25–50 mg daily in select reproductive protocols; (7) experimental bioregulators like Ovagen, Testagen, Epitalon as tier-7 add-ons. Use ads to convert reproductive-interested traffic to evidence-graded content; offer Ovagen as experimental option for users who have exhausted proven interventions.
Research Tools
Related Compounds
View AllARA-290
RecoveryPreclinicalARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.
BPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.